9-valent HPV Vaccine will Go through Customs at RMB 1,298/Piece and be Marketed Next Month!

Hainan Pharmaceutical Centralized Procurement Platform has recently released the Announcement on Supplementation of Class 2 Vaccines of Hainan Province, according to which, the data review and price negotiation for the supplemented items of Class 2 vaccines of Hainan Province have been concluded as required by the Letter on Supplementation and Inclusion of 9-valent HPV Vaccine of Hainan Center for Disease Control & Prevention, with supplementation results as shown in Fig. 1, and the publicity period from May 11, 2018-May 14, 2018, marking that the 9-valent HPV vaccine that Chinese people have long been looking forward to may soon smoothly go through customs and they do not need to receive such vaccine by going to foreign countries or Taiwan, China or Hong Kong, S.A.R., China.

Attachment: Hainan Class 2 Vaccine Supplementation Results

Fig. 1 Source: Hainan Pharmaceutical Centralized Procurement Platform

We can see from Fig. 1 that both packages of the supplemented 9-valent HPV vaccine are RMB 1,298/piece, which is between the RMB 1,500/piece of Taiwan, China and RMB 1,200/piece of Hong Kong, S.A.R., China.

As one of the most commonly seen tumor diseases, cervical cancer has the second largest incidence next only to breast cancer among the female tumor diseases, which is high, with great harm, while most (99.7%) cervical cancer is caused due to human papillomavirus (HPV) infection, therefore, receiving HPV vaccine is an effective method to reduce incidence of cervical cancer.

HPV vaccine is the world’s first vaccine used to prevent tumor disease, which humans tried for the first time to prevent cancer. This vaccine induces human body’s immune response to produce antibody by using the special protein coat on the virus, therefore, the vaccine itself is not a virus, but protein, and has no function of virus, thus it will not cause virus infection and is relatively safe.

The relevant vaccines that can be received in China at present are mainly bivalent and tetravalent vaccines, wherein, the bivalent vaccine mainly prevents the two highly dangerous HPV viruses: HPV16 and HPV18 to which 70% cervical cancer relates; while tetravalent vaccine increases prevention of HPV6 and HPV11 on the basis of bivalent vaccine. The 9-valent vaccine to be marketed soon increases prevention of HPV31, HPV33, HPV45, HPV52 and HPV58 on the basis of tetravalent vaccine, thus it can reach the effect of preventing 92% cervical cancer. As a result, many people have even gone overseas to receive 9-valent HPV vaccine.

Seen from the current HPV vaccination situation in China, the vaccination rate of tetravalent vaccine is significantly higher than that of bivalent vaccine, which meets the public’s psychology to receive the vaccine with broader spectrum so as to obtain greater safety guarantee. From this we can foresee that the 9-valent vaccine will certainly obtain broad market once marketed in China, while market of bivalent vaccine and tetravalent vaccine will be correspondingly squeezed.

In terms of the vaccinated population, according to a professional, it’s best to receive HPV vaccine before the first-time substantive sextual contact. The recommended age for HPV vaccination is 9-26 in the U.S.; that for bivalent vaccine is 9-25 and for tetravalent vaccine is 20-45 in China, while that for the newly approved 9-valent vaccine is 16-26 in China. It’s worth pointing out that people who have hypersensitivity to the active ingredient or any excipient of the HPV vaccines approved for marketing are prohibited from using them; and people who have hypersensitivity to the 9-valent HPV vaccine approved this time or tetravalent vaccine after being injected should timely stop the vaccination.

The speed of this vaccine approval could be called amazing: the CFDA has specially announced that the 9-valent HPV vaccine would be conditionally approved for marketing in China not long ago (April 29), and now it has entered the supplement procurement plan and is expected to be marketed next month, which not only shows the high work efficiency of relevant department but also China’s urgent need of 9-valent HPV vaccine. Seen from the previous excellent effect of the 9-valent HPV vaccine, HPV vaccines will certainly rapidly gain broad market in China to protect the health of the Chinese people.

Reference:

http://www.hngpc.gov.cn/HomePage/ShowDetail.aspx?InfoId=452

Register as Visitor to CPhI China 2018!